AU
UK
CA
NZ
IND
US
Last update at 2026-06-23T13:32:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 24.47M | 24.00M | -6.93100M | -21.30400M | -17.45900M |
| Minority interest | -0.28000M | -0.00100M | 0.00000M | 0.08M | 1.09M |
| Net income | 17.23M | 21.67M | -7.90100M | -24.41600M | -18.00700M |
| Selling general administrative | 3.55M | 2.81M | 4.48M | 9.86M | 50.64M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 83.33M | 49.93M | 50.51M | 53.25M | 44.45M |
| Reconciled depreciation | 13.86M | 7.37M | 6.04M | 0.01000M | 4.48M |
| Ebit | - | 11.10M | 1.80M | -12.30700M | -16.62100M |
| Ebitda | 47.49M | 40.36M | 7.84M | -7.02200M | -12.32800M |
| Depreciation and amortization | - | - | - | - | - |
| Non operating income net other | - | - | - | - | - |
| Operating income | 28.06M | 11.10M | 6.91M | -12.30700M | -16.58000M |
| Other operating expenses | - | -0.81900M | -0.74800M | -0.75300M | 0.89M |
| Interest expense | 9.16M | 8.99M | 8.73M | 8.53M | 0.65M |
| Tax provision | 6.97M | 2.33M | 0.97M | 3.19M | 0.60M |
| Interest income | 2.94M | 3.06M | 1.75M | 0.97M | 2.20M |
| Net interest income | -6.33100M | -6.40900M | -7.15600M | -7.74500M | 1.15M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | - | 2.33M | 0.97M | 3.19M | 0.60M |
| Total revenue | 102.09M | 65.07M | 60.95M | 62.49M | 66.50M |
| Total operating expenses | 74.03M | 53.97M | 54.04M | 74.80M | 83.08M |
| Cost of revenue | 18.76M | 15.14M | 10.44M | 9.25M | 22.06M |
| Total other income expense net | - | - | - | - | -0.87900M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 17.50M | 21.67M | -7.90100M | -24.49400M | -18.05700M |
| Net income applicable to common shares | - | 21.67M | -7.90100M | -24.41600M | -18.00700M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | - | 759.59M | 805.56M | 596.16M | 585.16M |
| Intangible assets | - | 366.84M | 372.73M | 26.64M | 49.22M |
| Earning assets | - | - | - | - | - |
| Other current assets | - | - | 10.88M | 3.48M | 5.26M |
| Total liab | - | 295.80M | 292.88M | 196.04M | 191.43M |
| Total stockholder equity | - | 456.93M | 505.28M | 400.12M | 393.73M |
| Deferred long term liab | - | - | 245.56M | 23.40M | 27.55M |
| Other current liab | - | 6.90M | 6.80M | 9.93M | 5.71M |
| Common stock | - | - | 4.56M | 3.91M | 3.91M |
| Capital stock | - | 4.56M | 4.56M | 3.91M | 3.91M |
| Retained earnings | - | 262.24M | 293.31M | 265.35M | 272.43M |
| Other liab | - | - | 102.62M | 9.04M | 12.38M |
| Good will | - | 24.00M | 24.00M | 1.44M | 1.44M |
| Other assets | - | - | 298.98M | 58.70M | 50.05M |
| Cash | - | 185.82M | 198.56M | 185.94M | 110.39M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | - | 194.95M | 21.24M | 21.79M | 15.71M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | - | - | - | - | 48.85M |
| Short term debt | - | - | - | - | - |
| Short long term debt | - | 171.07M | 0.13M | 0.13M | 0.13M |
| Short long term debt total | - | - | - | - | - |
| Other stockholder equity | - | - | 29.39M | 95.82M | 76.63M |
| Property plant equipment | - | - | 30.48M | 29.30M | 30.19M |
| Total current assets | - | 306.10M | 275.85M | 252.87M | 302.37M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | - | 354.10M | 395.44M | 370.63M |
| Short term investments | - | 55.13M | 23.65M | 26.91M | 157.82M |
| Net receivables | - | 34.08M | 27.68M | 28.14M | 20.54M |
| Long term debt | - | 0.56M | 167.15M | 163.02M | 159.11M |
| Inventory | - | 11.50M | 13.12M | 5.71M | 6.14M |
| Accounts payable | - | 10.66M | 8.30M | 5.95M | 5.52M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | - | - | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | - | -0.45000M | - | - | - |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | - | 453.50M | 529.71M | 343.29M | 282.80M |
| Capital lease obligations | - | 1.97M | 2.64M | 4.99M | 5.60M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 1.69M | 6.74M | 107.48M | -21.66700M | -64.85100M |
| Change to liabilities | - | -0.47300M | 0.61M | -1.03800M | -2.67500M |
| Total cashflows from investing activities | - | 24.86M | 75.45M | -48.68800M | -71.78100M |
| Net borrowings | - | -2.62400M | -1.78800M | -1.75200M | 165.59M |
| Total cash from financing activities | - | -27.24700M | -11.88400M | -34.46000M | 144.39M |
| Change to operating activities | - | -0.45800M | 1.78M | -2.07300M | -0.71200M |
| Net income | 17.23M | 21.67M | -7.90100M | -24.41600M | -18.00700M |
| Change in cash | -11.21800M | 12.62M | 75.55M | -100.30200M | 65.75M |
| Begin period cash flow | 198.56M | 185.94M | 110.39M | 210.69M | 144.94M |
| End period cash flow | 185.82M | 198.56M | 185.94M | 110.39M | 210.69M |
| Total cash from operating activities | 33.23M | 12.61M | 12.98M | -18.84700M | -10.16400M |
| Issuance of capital stock | 0.27M | - | 5.25M | - | 0.00000M |
| Depreciation | 13.86M | 5.16M | 5.06M | 5.22M | 4.39M |
| Other cashflows from investing activities | - | 3.06M | 0.81M | -9.78800M | 2.79M |
| Dividends paid | -15.60700M | - | - | - | - |
| Change to inventory | 1.62M | -6.07200M | 0.44M | -2.20600M | -0.69600M |
| Change to account receivables | - | 3.29M | -7.91500M | -3.71000M | 0.63M |
| Sale purchase of stock | -24.74700M | -19.74500M | -10.97200M | -25.33300M | -18.35300M |
| Other cashflows from financing activities | - | -4.87800M | -4.37500M | -7.37500M | -2.84100M |
| Change to netincome | - | -11.35800M | 19.99M | 8.84M | 6.81M |
| Capital expenditures | 7.31M | 5.49M | 4.12M | 2.25M | 1.90M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -13.31400M | -5.07200M | -5.13800M | -9.02700M | -3.45500M |
| Stock based compensation | 2.08M | 1.46M | 8.99M | 10.08M | - |
| Other non cash items | 6.84M | 6.21M | 4.15M | -7.90500M | -1.59800M |
| Free cash flow | 25.92M | 4.11M | 4.90M | -36.16000M | -19.83600M |
Sector: Healthcare Industry: Drug Manufacturers - General
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CMOPF Cosmo Pharmaceuticals N.V |
1.15 1.40% | 83.35 | 15.30 | 11.06 | 6.03 | 2.12 | 4.95 | 8.71 |
| LLY Eli Lilly and Company |
1.30 0.12% | 1103.38 | 78.14 | 31.95 | 16.34 | 45.83 | 16.65 | 54.36 |
| JNJ Johnson & Johnson |
3.96 1.71% | 235.25 | 29.17 | 14.33 | 3.74 | 5.18 | 3.80 | 15.22 |
| ABBV AbbVie Inc |
4.57 1.99% | 234.58 | 86.32 | 14.33 | 5.89 | 50.46 | 7.04 | 24.44 |
| AZN AstraZeneca PLC |
3.39 1.92% | 179.82 | 30.69 | 19.23 | 5.30 | 6.45 | 5.72 | 17.23 |
Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delivers budesonide directly to the lumen of the colon; Eleview, a submucosal injectable composition to allow endoscopists with a faster and less risky excision of gastrointestinal lesions; Lumeblue, a diagnostic drug for the visualisation of colorectal lesions during colonoscopies; Aemcolo/Relafalk, a pharmaceutical drug product in form of tablets that is approved for the treatment of travelers' diarrhoea; and Byfavo, an intravenous benzodiazepine sedative/anesthetic. It is also developing Breezula, a novel androgen receptor inhibitor, which is in Phase III trials and targets androgen receptors in the scalp; Rifamycin SV MMX " IBS-D, a formulation that is in Phase III clinical trial to treat colonic infections and irritable bowel syndrome with diarrhoea; CB-03-10, an oral androgen receptor antagonist, which is in Phase I clinical trial for treatment solid tumors; CB-01-33 that is in preclinical studies for the treatment of bile acid diarrhea; and CB-01-35, an enema solution, which is in Phase II clinical trial for the treatment of distal ulcerative colitis and proctitis. The company has development, distribution, and licensing agreements with Bausch Health, Ferring, China Medical System Holdings Limited, Medtronic, RedHill Biopharma Ltd., Sun Pharmaceutical Industries Ltd., 3SBio, InfectoPharm, and Hyphens Pharma International Limited. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.
Riverside II, Dublin, Ireland, 2
| Name | Title | Year Born |
|---|---|---|
| Mr. Mauro Severino Ajani | Founder & Exec. Chairman | 1955 |
| Mr. Alessandro E. Della Cha LL.M | CEO & Exec. Director | 1963 |
| Mr. Ngo Dinh Nhan | Head of R&D - AI & Biomedical IT | 1979 |
| Mr. Giulio Evangelisti | Head of Production, AI & Biomedical IT | 1970 |
| Mr. Niall Donnelly | Chief Financial Officer | 1972 |
| Mr. Marco Lecchi | Chief Operating Officer | 1964 |
| Mr. Davide Malavasi | Qualified Person & Technical Director | 1973 |
| Mr. Luigi Longo | Chief Scientific Officer | 1979 |
| Ms. Hazel Winchester | Head of Investor Relations | 1971 |
| Mr. Biagio Vigano | Chief People Officer | 1974 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...